Top 20

The year 2024 is the 20

Informations de copyright

© 2024 Ou et al.

Déclaration de conflit d'intérêts

Dr Sai-Hong Ou reports grants, personal fees from Pfizer, Jansen, Daiichi Sankyo; personal fees from Anheart Therapeutics, Bayer, Dava Oncology LLP, OncLive, BMS; grants from Revolution Medicines, Mirati, Merus; grants and/or stock ownership from Nuvalent, MBrace Therapeutics, BlossomHill Therapeutics, Turning Point Therapeutics, Elevation Oncology, and Lilly, outside the submitted work. Dr Xiuning Le reports personal fees from AstraZeneca, EMD Serono, Lilly, Boehringer Ingelheim, Regeneron, Bayer, Teligene, SystImmune, Janssen, Daiichi, AbbVie, ArriVent, and Abion, outside the submitted work. Dr Misako Nagasaka reports personal fees from AstraZeneca, Daiichi Sankyo, Novartis, EMD Serono, Pfizer, Lilly, Genentech, Regeneron, BMS, Caris Life Sciences, Mirati, Takeda, Janssen, Blueprint Medicine; non-financial support from AnHeart Therapeutics, outside the submitted work. Dr Thanyanan Reungwetwattana reports grants, personal fees from AstraZeneca, Roche, Novartis, MSD, Yuhan; personal fees from Pfizer, J&J, BMS, and Amgen, outside the submitted work. Prof. Dr. Myung-Ju Ahn reports personal fees from AstraZeneca, Yuhan, TAKEDA, Daiichi Sankyo, Alpha pharmaceuticals, Merck, Amgen, MSD, Roche, and voronoi, outside the submitted work. Dr Edgardo Santos reports personal fees from AstraZeneca, Genentech, Sanofi, Regeneron, AbbVie, Novartis, Amgen, Boehringer-Ingelheim, BMS, Eli Lilly, EMD Serono, G1 Therapeutics, Jazz Pharmaceuticals, Merck, Mirati, Pfizer, Coherus, Sobi, Takeda, and Johnson and Johnson, during the conduct of the study. Dr Elaine Shum reports personal fees from AstraZeneca, Johnson & Johnson, Genentech, Regeneron, Gilead, Bristol Meyers Squibb, Boehringer Ingelheim; grants from Delfi Diagnostics, outside the submitted work. Dr Antonio Calles reports personal fees, grants and/or non-financial support from AstraZeneca, Amgen, Boehringer-Ingelheim, Bayer, Pfizer, Roche, MSD, BMS, Novartis, Lilly, Takeda, and PharmaMar. Dr Gilberto Lopes reports stock ownership from Lucence Diagnostics, Xilis, Biomab, Morphometrix, and CDR-Life; honoraria from Boehringer Ingelheim, Blueprint Medicines, AstraZeneca, Merck, and Janssen; consulting or advisory role for Pfizer and AstraZeneca; research funding from AstraZeneca, Lucence, Xilis, E.R. Squibb Sons, LLC; research funding to his institution from Merck Sharp & Dohme, EMD Serono, AstraZeneca, Blueprint Medicines, Tesaro, Bavarian Nordic, NOVARTIS, G1 Therapeutics, adaptimmune, BMS, GSK, AbbVie, Rgenix, Pfizer, Roche, Genentech, Lilly, Janssen; travel, accommodations and expenses from Boehringer Ingelheim, Pfizer, E.R. Squibb Sons, LLC, Janssen, Seattle Genetics, Celgene, Ibsen, Pharmacyclics, Merck, AstraZeneca, Seagen; and Mirati Therapeutics. Dr Junko Tanizaki reports personal fees from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi sankyo Co., Ltd, Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., MSD K.K., Nihon Medi-Physics Co., Ltd, Nippon Kayaku Co., Ltd., Taiho Pharmaceutical Co. Ltd. K., Ono pharmaceutical Co. Ltd., and Pfizer Japan Inc., outside the submitted work. Dr Hidehito Horinouchi reports grants and/or personal fees from Roche/Chugai, AstraZeneca, BMS/ONO, AbbVie, Daiichi-Sankyo, Kyowa-Kirin, Taiho, and Guardant, outside the submitted work. Dr Marina Garassino reports personal fees from AstraZeneca, during the conduct of the study. Professor Sanjay Popat reports personal fees from Ahneart, Amgen, AstraZeneca, Bayer, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Ellipses, EQRx, GlaxoSmithKline, Guardant Health, Janssen, Lilly, Merck KGaA, Mirati, MSD, Novocure, Novartis, Pfizer, PharmaMar, Pierre Fabre, Roche, Sanofi, Takeda, and Turning Point Therapeutics, during the conduct of the study. Professor Benjamin Besse is advisory board of Daiichi Sankyo, F. Hoffmann-La Roche Ltd, steering committee of and counsel for Janssen, Taiho, AstraZeneca, and Takeda, during the conduct of the study. Dr Ross Soo reports grants and/or personal fees from Bayer, AbbVie, Amgen, Astra-Zeneca, BMS, Boehringer Ingelheim, Daiichi Sankyo, J INTS BIO, Janssen, Lily, Merck, Merck Serono, Novartis, Pfizer, Puma, Roche, Sanofi, Taiho, Takeda, ThermoFisher, and Yuhan, outside the submitted work. The authors report no other conflicts of interest in this work.